DE60214198D1 - Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen - Google Patents
Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasenInfo
- Publication number
- DE60214198D1 DE60214198D1 DE60214198T DE60214198T DE60214198D1 DE 60214198 D1 DE60214198 D1 DE 60214198D1 DE 60214198 T DE60214198 T DE 60214198T DE 60214198 T DE60214198 T DE 60214198T DE 60214198 D1 DE60214198 D1 DE 60214198D1
- Authority
- DE
- Germany
- Prior art keywords
- inhibitors
- src
- pyrimidines
- isoxazolyl
- protein kinases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30296901P | 2001-07-03 | 2001-07-03 | |
US302969P | 2001-07-03 | ||
PCT/US2002/018956 WO2003004492A1 (en) | 2001-07-03 | 2002-06-14 | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60214198D1 true DE60214198D1 (de) | 2006-10-05 |
DE60214198T2 DE60214198T2 (de) | 2007-08-09 |
Family
ID=23170022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60214198T Expired - Lifetime DE60214198T2 (de) | 2001-07-03 | 2002-06-14 | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
Country Status (9)
Country | Link |
---|---|
US (2) | US6689778B2 (de) |
EP (1) | EP1417205B1 (de) |
JP (1) | JP4342937B2 (de) |
AT (1) | ATE337312T1 (de) |
CA (1) | CA2452603A1 (de) |
DE (1) | DE60214198T2 (de) |
ES (1) | ES2271283T3 (de) |
HK (1) | HK1065540A1 (de) |
WO (1) | WO2003004492A1 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001292670A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA03005606A (es) * | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
JP4342937B2 (ja) * | 2001-07-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | SrcおよびLckタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン |
PL372198A1 (en) * | 2002-02-06 | 2005-07-11 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
ATE468336T1 (de) * | 2002-03-15 | 2010-06-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
DK1532145T3 (da) * | 2002-08-02 | 2007-01-15 | Vertex Pharma | Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3 |
AU2003270350A1 (en) * | 2002-09-06 | 2004-03-29 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use in the treatment of ischemic diseases |
KR20120032574A (ko) * | 2002-10-03 | 2012-04-05 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
US7592340B2 (en) * | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
JPWO2005080392A1 (ja) | 2004-02-19 | 2007-08-02 | 武田薬品工業株式会社 | ピラゾロキノロン誘導体およびその用途 |
EP1809614B1 (de) * | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazin-kinasehemmer |
CA2578283A1 (en) | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
JP5100126B2 (ja) * | 2004-12-28 | 2012-12-19 | あすか製薬株式会社 | ピリミジニルイソオキサゾール誘導体 |
JP2008543775A (ja) * | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | 眼の障害を治療するための方法および組成物 |
US7737151B2 (en) * | 2005-08-18 | 2010-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
SG166827A1 (en) * | 2005-11-03 | 2010-12-29 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
WO2007127366A2 (en) * | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
CA2668429A1 (en) * | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
MX2009006690A (es) * | 2006-12-19 | 2009-07-31 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
MX2009009592A (es) * | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopiridinas utiles como inhibidores de proteinas cinasas. |
MX2009009591A (es) * | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
MX2009009590A (es) * | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
AU2008247594A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
MX2009011811A (es) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
MX2009011810A (es) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Tiazoles y pirazoles utiles como inhibidores de cinasa. |
JP2010528021A (ja) * | 2007-05-24 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール |
EP2176261B1 (de) * | 2007-07-31 | 2012-12-19 | Vertex Pharmaceuticals Incorporated | Verfahren für die zubereitung von 5-fluor-1h-pyrazolo [3, 4-b] pyridin-3-amin und derivaten davon |
WO2009027450A1 (de) | 2007-08-29 | 2009-03-05 | Boehringer Ingelheim International Gmbh | Neue bradykinin b1-antagonisten |
EP2265607B1 (de) | 2008-02-15 | 2016-12-14 | Rigel Pharmaceuticals, Inc. | Pyrimidin-2-aminverbindungen und ihre verwendung als inhibitoren von jak-kinasen |
JP2012501971A (ja) * | 2008-09-03 | 2012-01-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶および共結晶を含む薬学的処方物 |
AP2011005808A0 (en) * | 2009-02-26 | 2011-08-31 | Boehringer Ingelheim Int | Compounds as bradykinin B1 antagonists. |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
PT2841428T (pt) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Inibidores de adn-pk |
EP2922828B1 (de) | 2012-11-21 | 2020-07-08 | PTC Therapeutics, Inc. | 4,6-diamino-pyrimidin-derivate als bmi-1 inhibitoren zur behandlung von krebs |
DK3527563T3 (da) | 2013-03-12 | 2021-12-06 | Vertex Pharma | Dna-pk-inhibitorer |
EA034866B1 (ru) * | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
SG11201602962PA (en) | 2013-10-17 | 2016-05-30 | Vertex Pharma | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
EP3071553A4 (de) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituierte pyridin- und pyrazin-bmi-1-hemmer |
CN108064274A (zh) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
BR112018074232A2 (pt) * | 2016-05-26 | 2019-03-06 | Zeno Royalties & Milestones, LLC | compostos inibidores de egfr |
MX2019003317A (es) | 2016-09-27 | 2019-08-05 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
CA3090063A1 (en) * | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
EP3914698A1 (de) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Kulturmedien für pluripotente stammzellen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020030791A (ko) | 1999-08-12 | 2002-04-25 | 버텍스 파마슈티칼스 인코포레이티드 | c-JUN N-말단 키나제(JNK) 및 기타의 단백질키나제 억제제 |
WO2002083668A1 (en) * | 2001-04-10 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Isoxaxole derivatives as inhibitors of src and other protein kinases |
JP4342937B2 (ja) * | 2001-07-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | SrcおよびLckタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン |
-
2002
- 2002-06-14 JP JP2003510659A patent/JP4342937B2/ja not_active Expired - Fee Related
- 2002-06-14 DE DE60214198T patent/DE60214198T2/de not_active Expired - Lifetime
- 2002-06-14 CA CA002452603A patent/CA2452603A1/en not_active Abandoned
- 2002-06-14 US US10/171,895 patent/US6689778B2/en not_active Expired - Fee Related
- 2002-06-14 EP EP02744355A patent/EP1417205B1/de not_active Expired - Lifetime
- 2002-06-14 ES ES02744355T patent/ES2271283T3/es not_active Expired - Lifetime
- 2002-06-14 WO PCT/US2002/018956 patent/WO2003004492A1/en active IP Right Grant
- 2002-06-14 AT AT02744355T patent/ATE337312T1/de not_active IP Right Cessation
-
2003
- 2003-12-04 US US10/728,113 patent/US20050049246A1/en not_active Abandoned
-
2004
- 2004-10-25 HK HK04108356A patent/HK1065540A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE337312T1 (de) | 2006-09-15 |
HK1065540A1 (en) | 2005-02-25 |
US6689778B2 (en) | 2004-02-10 |
JP4342937B2 (ja) | 2009-10-14 |
EP1417205A1 (de) | 2004-05-12 |
WO2003004492A1 (en) | 2003-01-16 |
US20050049246A1 (en) | 2005-03-03 |
CA2452603A1 (en) | 2003-01-16 |
DE60214198T2 (de) | 2007-08-09 |
EP1417205B1 (de) | 2006-08-23 |
JP2004536114A (ja) | 2004-12-02 |
US20030171389A1 (en) | 2003-09-11 |
ES2271283T3 (es) | 2007-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60214198D1 (de) | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen | |
ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
MXPA03010961A (es) | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. | |
DE60330895D1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
WO2002083667A3 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
ATE466581T1 (de) | Verbindungen auf pyrimidin-basis als gsk-3-hemmer | |
NO20070529L (no) | Kinazolindionderivater som parp-inhibitorer | |
BR0313176A (pt) | Composições de pirazol úteis como inibidores de gsk-3 | |
ATE469888T1 (de) | Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren | |
ATE536353T1 (de) | 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren | |
AU2003297160A1 (en) | Benzisoxazole derivatives useful as inhibitors of protein kinases | |
BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |